01276nas a2200409   4500000000100000000000100001008004100002653003100043653002800074653004000102653002600142653001900168653002800187653002200215653001100237653002700248653003000275653002400305653006700329653003400396653004200430653003600472653002800508653003400536653001900570100001500589700001600604700001600620700001500636700001700651700001500668245011600683250001500799300001400814490000700828020003100835       2022                            d10aAdministration, Inhalation10aAdrenal Cortex Hormones10aAdrenergic beta-2 Receptor Agonists10aBronchodilator Agents10aChlorobenzenes10aCross-Sectional Studies10aDrug Combinations10aHumans10aMuscarinic Antagonists10aNebulizers and Vaporizers10aPrimary health care10a*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy10aQuinuclidines/adverse effects10achronic obstructive pulmonary disease10amultiple-inhaler triple therapy10apatient characteristics10asingle-inhaler triple therapy10atriple therapy1 aK. Rothnie1 aS. Joksaite1 aL. Sansbury1 aC. Compton1 aV. Di Boscio1 aA. Ismaila00aCharacteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England  a2022/07/01  a1455-14660 v17  a1176-9106 (Print)1176-9106